Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different drug exposure levels affect treatment effectiveness or safety in patients with relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutations.

Researchers used population pharmacokinetic (popPK) and exposure-response (ER) modeling to analyze data from clinical trials involving healthy volunteers and AML patients. The goal was to understand how factors such as age, weight, organ function, food intake, and other medications influence ziftomenib exposure and patient outcomes.

The analyses showed that ziftomenib exposure was generally consistent across patient groups, and most patient characteristics did not meaningfully impact how the drug was processed in the body. Importantly, higher or lower drug exposure levels were not associated with major differences in efficacy or safety, indicating that the drug has a wide therapeutic margin.

The study also found that antifungal azole medications, which are commonly used in AML patients, could be safely co-administered without requiring ziftomenib dose adjustments.

Overall, these modeling results supported the use of a 600 mg once-daily dose of ziftomenib in patients with relapsed or refractory NPM1-mutated AML and demonstrated how model-informed drug development approaches can help optimize dosing and support clinical decision-making.